DE69810034T2 - Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen - Google Patents

Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen

Info

Publication number
DE69810034T2
DE69810034T2 DE69810034T DE69810034T DE69810034T2 DE 69810034 T2 DE69810034 T2 DE 69810034T2 DE 69810034 T DE69810034 T DE 69810034T DE 69810034 T DE69810034 T DE 69810034T DE 69810034 T2 DE69810034 T2 DE 69810034T2
Authority
DE
Germany
Prior art keywords
ppm
formula
trans
compound
meanings given
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69810034T
Other languages
German (de)
English (en)
Other versions
DE69810034D1 (de
Inventor
Jean-Christophe Harmange
Francoise Lejeune
Mark Millan
Jean-Louis Peglion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Application granted granted Critical
Publication of DE69810034D1 publication Critical patent/DE69810034D1/de
Publication of DE69810034T2 publication Critical patent/DE69810034T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69810034T 1997-09-01 1998-09-01 Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen Expired - Lifetime DE69810034T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710852A FR2767825A1 (fr) 1997-09-01 1997-09-01 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
DE69810034D1 DE69810034D1 (de) 2003-01-23
DE69810034T2 true DE69810034T2 (de) 2003-08-14

Family

ID=9510643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69810034T Expired - Lifetime DE69810034T2 (de) 1997-09-01 1998-09-01 Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen

Country Status (18)

Country Link
US (1) US6025356A (https=)
EP (1) EP0899267B1 (https=)
JP (1) JP4417451B2 (https=)
CN (1) CN1088064C (https=)
AT (1) ATE229513T1 (https=)
AU (1) AU740928C (https=)
BR (1) BR9803933A (https=)
CA (1) CA2246482C (https=)
DE (1) DE69810034T2 (https=)
DK (1) DK0899267T3 (https=)
ES (1) ES2189108T3 (https=)
FR (1) FR2767825A1 (https=)
HU (1) HU226059B1 (https=)
NO (1) NO311218B1 (https=)
NZ (1) NZ331637A (https=)
PL (1) PL194533B1 (https=)
PT (1) PT899267E (https=)
ZA (1) ZA987963B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1534679A4 (en) * 2002-08-30 2007-06-06 Biostratum Inc INHIBITORS OF POST-AMADORI ADVANCED GLYCATION ENDPRODUCTS
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
FR2906249B1 (fr) * 2006-09-26 2008-12-19 Servier Lab Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
CN102131790A (zh) * 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
WO1991019719A1 (en) * 1990-06-15 1991-12-26 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics

Also Published As

Publication number Publication date
DK0899267T3 (da) 2003-03-10
HU226059B1 (en) 2008-04-28
CN1222516A (zh) 1999-07-14
ZA987963B (en) 1999-03-04
CA2246482A1 (fr) 1999-03-01
ES2189108T3 (es) 2003-07-01
DE69810034D1 (de) 2003-01-23
PT899267E (pt) 2003-04-30
HUP9801951A2 (hu) 2000-02-28
NO984007D0 (no) 1998-08-31
BR9803933A (pt) 2001-04-24
NZ331637A (en) 1999-07-29
HUP9801951A3 (en) 2000-04-28
EP0899267A1 (fr) 1999-03-03
AU740928C (en) 2002-05-16
PL328285A1 (en) 1999-03-15
ATE229513T1 (de) 2002-12-15
AU8302498A (en) 1999-03-11
CA2246482C (fr) 2002-11-26
HU9801951D0 (en) 1998-11-30
HK1020340A1 (en) 2000-04-14
JPH11130759A (ja) 1999-05-18
NO984007L (no) 1999-03-02
CN1088064C (zh) 2002-07-24
FR2767825A1 (fr) 1999-02-26
JP4417451B2 (ja) 2010-02-17
NO311218B1 (no) 2001-10-29
PL194533B1 (pl) 2007-06-29
EP0899267B1 (fr) 2002-12-11
AU740928B2 (en) 2001-11-15
US6025356A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
DE69722220T2 (de) 4-substituierte beta-carboline als immunomodulatoren
DE69032725T2 (de) ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
DE69300532T2 (de) Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE69621626T2 (de) Acylierte derivate von melatonin und dessen analoge als arzneimittel
DE69231854T2 (de) Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
DE69934238T2 (de) Azabicyclo-verbindungen welche die inhibition der zell adhesion modulieren
DE60009663T2 (de) Piperidin-, tetrahydropyridin- und piperazin-derivate, ihre herstellung und anwendung
DE69326637T2 (de) 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen
DE60302137T2 (de) Piperidinderivate
EP1758860B1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE69935331T2 (de) Verfahren und verbindungen zur behandlung der depression
DE69510553T2 (de) Isothioharnstoff-derivate als no synthase hemmer
DE60103140T2 (de) Propancarbonsäure-amidoxim derivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese entahlten
EP1309585B1 (de) Neue indolderivate und deren verwendung als arzneimittel
DE2363052A1 (de) 3-phenyl-3-aminoalkyl-2,6-dioxo-tetraund -hexahydropyridine, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
DE3402601A1 (de) Neue pharmazeutisch aktive 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate, deren herstellung und verwendung
DE69810034T2 (de) Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen
DE3620643A1 (de) Thiazole, ihre herstellung und verwendung
DE69810560T2 (de) Indanol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69503745T2 (de) 3-Alkoxybenzylpiperidin-Derivate as melatonergisches Mittel
DE10048715A1 (de) Verwendung von Aminosäure zur Behandlung von Schmerz
DE2362754C2 (de) Cyclopropylalkylaminoreste enthaltende Oxazolinverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2000319259A (ja) 神経変性疾患を治療するための化合物
DE69806750T2 (de) Amidinderivate als inhibitoren von no-synthase
DE68905363T2 (de) Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition